Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis

Lancet Oncology

Volumn 8, Issue 10, 2007, Pages 898-911

  Golfinopoulos, Vassilis ^a   Salanti, Georgia ^a   Pavlidis, Nicholas ^a   Ioannidis, John PA ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FLUOROURACIL DERIVATIVE; FOLINIC ACID; IRINOTECAN; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; RALTITREXED; TEGAFUR;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HUMAN; META ANALYSIS; MONOTHERAPY; MONTE CARLO METHOD; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SENSITIVITY ANALYSIS; SURVIVAL TIME; SYSTEMATIC REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 34748918351     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70281-4     Document Type: Article

References (67)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2003. National Cancer Institute. Bethesda, MD.
3. Nelson R., Persky V., and Turyk M. Determination of factors responsible for the declining incidence of colorectal cancer. Dis Colon Rectum 42 (1999) 741-752
4. Chen S., and Bilchik A. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg 244 (2006) 602-610
5. Wolmark N., Rockette H., Mamounas E., et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17 (1999) 3553-3559
6. Krook J., Moertel C., Gunderson L., et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 324 (1991) 709-715
7. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
8. Simmonds P. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 321 (2000) 531-535
9. Thirion P., Michiels S., Pignon J., et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 22 (2004) 3766-3775
10. Salanti G, Higgins PTJ, Ades EA, Ioannidis PAJ. Evaluation of networks of randomized trials. Stat Methods Med Res (in press).
11. Caldwell D., Ades A., and Higgins J. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331 (2005) 897-900
12. Hopewell S., Clarke M., Lusher A., Lefebvre C., and Westby M. A comparison of handsearching versus MEDLINE searching to identify reports of randomised controlled trials. Stat Med 21 (2002) 1625-1634
13. Parmar M., Torri V., and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17 (1998) 2815-2834
14. Higgins J., and Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002) 1539-1558
15. Glenny A., Altman D., Song F., et al. Indirect comparisons of competing interventions. Health Technol Assess 9 (2005) 1-134 iii-iv.
16. Baker S., and Kramer B. The transitive fallacy for randomised trials: if A bests B and B bests C in separate trials, is A better than C?. BMC Med Res Methodol 2 (2002) 13
17. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 21 (2002) 2313-2324
18. Ioannidis J. Indirect comparisons: the mesh and mess of clinical trials. Lancet 368 (2006) 1470-1472
19. Rougier P., Lepille D., Bennouna J., et al. Antitumor activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. Ann Oncol 13 (2002) 1558-1567
20. Comella P., Crucitta E., De Vita F., et al. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group. Ann Oncol 13 (2002) 866-873
21. Maiello E., Gebbia V., Giuliani F., et al. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group. Ann Oncol 11 (2000) 1045-1051
22. Scheithauer W., Kornek G., Brugger S., et al. Randomised phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. Cancer Invest 20 (2002) 60-68
23. Comba A.Z., Blajman C., Richardet E., et al. A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur J Cancer 37 (2001) 1006-1013
24. Tournigand C., Andre T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study. J Clin Oncol 22 (2004) 229-237
25. Goldberg R., Sargent D., Morton R., et al. A randomised controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004) 23-30
26. Rothenberg M., Oza A., Bigelow R., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21 (2003) 2059-2069
27. Kabbinavar F., Hurwitz H., Fehrenbacher L., et al. Phase II, randomised trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
28. Becouarn Y., Gamelin E., Coudert B., et al. Randomised multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients. J Clin Oncol 19 (2001) 4195-4201
29. Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicenter randomised trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18 (2000) 136-147
30. De Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
31. Douillard J., Cunningham D., Roth A., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 (2000) 1041-1047
32. Rougier P., Van Cutsem E., Bajetta E., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352 (1998) 1407-1412
33. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
34. Saltz L., Cox J., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 (2000) 905-914
35. Delaunoit T., Goldberg R., Sargent D., et al. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer 101 (2004) 2170-2176
36. Kemeny N., Garay C., Gurtler J., et al. Randomised multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 22 (2004) 4753-4761
37. Kabbinavar F., Schulz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomised phase II trial. J Clin Oncol 23 (2005) 3697-3705
38. Graeven U., Ridwelski K., Artandi M., et al. Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer. Oncol Rep 13 (2005) 681-688
39. Comella P., Massidda B., Filippelli G., et al. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i·v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial. Ann Oncol 16 (2005) 878-886
40. Kalofonos H., Aravantinos G., Kosmidis P., et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomised, phase II study. Ann Oncol 16 (2005) 869-877
41. Hurwitz H., Fehrenbacher L., Hainsworth J., et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23 (2005) 3502-3508
42. Colucci G., Gebbia V., Paoletti G., et al. Phase III randomised trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23 (2005) 4866-4875
43. Kohne C., Van Cutsem E., Wils J., et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23 (2005) 4856-4865
44. Feliu J., Castanon C., Salud A., et al. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer. Br J Cancer 93 (2005) 1230-1235
45. Hospers G., Schaapveld M., Nortier J., et al. Randomised phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer. Ann Oncol 17 (2006) 443-449
46. Souglakos J., Androulakis N., Syrigos K., et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 94 (2006) 798-805
47. Goldberg R., Sargent D., Morton R., et al. Randomised controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 24 (2006) 3347-3353
48. Gennatas C., Papaxoinis G., Michalaki V., et al. A prospective randomised study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma. J Chemother 18 (2006) 538-544
49. Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25 (2007) 1670-1676
50. Giantonio J., Catalano J., Meropol J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 25 (2007) 1539-1544
51. Graeven U., Arnold D., Reinacher-Schick A., et al. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. Onkologie 30 (2007) 169
52. Bajetta E., Di Bartolomeo M., Buzzoni R., et al. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Br J Cancer 96 (2007) 439-444
53. Koopman M., Antonini N., Douma J., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370 (2007) 135-142
54. Seymour M., Maughan T., Ledermann J., et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370 (2007) 143-152
55. Tsavaris N., Kosmas C., Skopelitis H., et al. Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomised study. Chemotherapy 53 (2007) 282-291
56. Van Cutsem E., Nowacki M., Lang I., et al. Randomised phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. Proc Am Soc Clin Oncol 25 18S suppl (2007) abstr 4000.
57. Saltz L., Clarke S., Diaz-Rubio E., et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/ NO16966, a randomised phase III trial in first-line metastatic colorectal cancer. Proc Am Soc Clin Oncol 25 170S suppl (2007) abstr 4028.
58. Meyerhardt J., and Mayer R. Systemic therapy for colorectal cancer. N Engl J Med 352 (2005) 476-487
59. Johnson R., Ringland C., Stokes J., et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 7 (2006) 741-746
60. Sandler A., Gray R., Perry M., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 352 (2005) 476-487
61. Ioannidis JPA, Patsopoulos N, Evangelou E. Uncertainty of heterogeneity estimates in meta-analysis. BMJ (in press).
62. Bokemeyer C., Bondarenko I., Makhson A., et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomised phase II study. Proc Am Soc Clin Oncol 25 172 suppl (2007) abstr 4035.
63. Maughan T. Cetuximab (C), oxaliplatin (Ox), and fluoropyrimidine (Fp): toxicity during the first 12 weeks of treatment for the first 804 patients entered into the MRC COIN (CR10) trial. Proc Am Soc Clin Oncol 25 181 suppl (2007) abstr 4070.
64. Van Cutsem E., Peeters M., Siena S., et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 (2007) 1658-1664
65. Montori V., Devereaux P., Adhikari N., et al. Randomised trials stopped early for benefit: a systematic review. JAMA 294 (2005) 2203-2209
66. Ioannidis J. Effect of the statistical significance of results on the time to completion and publication of randomised efficacy trials. JAMA 279 (1998) 281-286
67. Trikalinos T., and Ioannidis J. Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data. J Clin Epidemiol 54 (2001) 245-252